EA201891241A1 - 1,3,4-тиадиазольные соединения и их применение в лечении рака - Google Patents

1,3,4-тиадиазольные соединения и их применение в лечении рака

Info

Publication number
EA201891241A1
EA201891241A1 EA201891241A EA201891241A EA201891241A1 EA 201891241 A1 EA201891241 A1 EA 201891241A1 EA 201891241 A EA201891241 A EA 201891241A EA 201891241 A EA201891241 A EA 201891241A EA 201891241 A1 EA201891241 A1 EA 201891241A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrogen
methoxy
tiadiazolic
cancer
compounds
Prior art date
Application number
EA201891241A
Other languages
English (en)
Inventor
Морис Реймонд Верскойл Финлей
Йоханнес Вилхелмус Мария Ниссинк
Марк Дэвид Чарльз
Original Assignee
Астразенека Аб
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, Кэнсер Рисерч Текнолоджи Лимитед filed Critical Астразенека Аб
Publication of EA201891241A1 publication Critical patent/EA201891241A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединение формулы (I)или его фармацевтически приемлемая соль, где Q может представлять собой 1,2,4-триазин-3-ил, пиридазин-3-ил, 6-метилпиридазин-3-ил или 6-фторпиридазин-3-ил; Rможет представлять собой водород, метокси, трифторметокси, оксетан-3-ил, 3-фторазетидин-1-ил, 3-метоксиазетидин-1-ил или 3,3-дифторазетидин-1-ил; Rможет представлять собой водород или фтор; Rможет представлять собой водород или метокси и Rможет представлять собой метокси, этокси или метоксиметил; при условии, что если Rпредставляет собой водород, метокси или трифторметокси, то Rне представляет собой водород, и/или Rпредставляет собой метоксиметил. Соединение формулы (I) может ингибировать глутаминазу, например, GLS1.
EA201891241A 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака EA201891241A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
EA201891241A1 true EA201891241A1 (ru) 2019-01-31

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891241A EA201891241A1 (ru) 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака

Country Status (23)

Country Link
US (3) US10323028B2 (ru)
EP (1) EP3383873B1 (ru)
JP (1) JP6999550B2 (ru)
KR (1) KR20180083942A (ru)
CN (1) CN108349966B (ru)
AR (1) AR106874A1 (ru)
AU (1) AU2016363718B2 (ru)
BR (1) BR112018010806A2 (ru)
CA (1) CA3005495C (ru)
CL (1) CL2018001407A1 (ru)
CO (1) CO2018006928A2 (ru)
EA (1) EA201891241A1 (ru)
ES (1) ES2914333T3 (ru)
IL (1) IL259510A (ru)
MX (1) MX2018006532A (ru)
NI (1) NI201800064A (ru)
PH (1) PH12018501131A1 (ru)
RU (1) RU2018123714A (ru)
SG (1) SG11201803810XA (ru)
SV (1) SV2018005702A (ru)
TN (1) TN2018000127A1 (ru)
TW (1) TW201733587A (ru)
WO (1) WO2017093299A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
JP7275053B2 (ja) * 2017-06-13 2023-05-17 メッドシャイン ディスカバリー インコーポレイテッド Ｇｌｓ１阻害剤としての化合物
WO2020078350A1 (zh) 2018-10-16 2020-04-23 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ES2761866T3 (es) 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
DK2920168T3 (da) * 2012-11-16 2021-10-18 Calithera Biosciences Inc Heterocykliske glutaminase-inhibitorer
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6783663B2 (ja) 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
US20150258082A1 (en) * 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
BR112018010806A2 (pt) 2018-11-27
EP3383873A1 (en) 2018-10-10
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
IL259510A (en) 2018-07-31
US10981904B2 (en) 2021-04-20
RU2018123714A (ru) 2020-01-09
PH12018501131A1 (en) 2019-01-21
SG11201803810XA (en) 2018-06-28
EP3383873B1 (en) 2022-03-09
TN2018000127A1 (en) 2019-10-04
CA3005495C (en) 2023-12-12
CN108349966A (zh) 2018-07-31
NI201800064A (es) 2018-10-18
CL2018001407A1 (es) 2018-10-12
AU2016363718B2 (en) 2019-11-14
WO2017093299A1 (en) 2017-06-08
JP6999550B2 (ja) 2022-02-10
SV2018005702A (es) 2018-11-27
TW201733587A (zh) 2017-10-01
CO2018006928A2 (es) 2018-10-10
US20210246131A1 (en) 2021-08-12
US11753405B2 (en) 2023-09-12
CN108349966B (zh) 2022-02-15
AU2016363718A1 (en) 2018-07-12
JP2018535986A (ja) 2018-12-06
US10323028B2 (en) 2019-06-18
CA3005495A1 (en) 2017-06-08
US20190389853A1 (en) 2019-12-26
AR106874A1 (es) 2018-02-28
ES2914333T3 (es) 2022-06-09
KR20180083942A (ko) 2018-07-23

Similar Documents

Publication Publication Date Title
EA201891241A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
GEP20237506B (en) Pcsk9 antagonist compounds
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
CR20200376A (es) Inhibidores de cd73
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PH12019501919A1 (en) Dioxolane analogues of uridine for the treatment of cancer
EA201990833A1 (ru) Соединение пиридина
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201492104A1 (ru) Ингибитор jak1/2
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)